Title:
COMBINATION THERAPY FOR NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS
Document Type and Number:
WIPO Patent Application WO/2018/126016
Kind Code:
A8
Abstract:
The innovation is directed to a method for treating a CCR5 and/or CCR2 mediated disease such as nonalcoholic steatohepatitis (NASH) comprising administering an effective amount of a C-C Chemokine receptor 5 (CCR5) antagonist (e.g., maraviroc or vicriviroc or cenicriviroc) and/or an effective amount of a C-C Chemokine receptor 2 (CCR2) antagonist, or a CCR5/CCR2 antagonist together with an effective amount of farnesoid X receptor (FXR) agonist (e.g., obeticholic acid (OCA)). An "effective amount" can be a regular clinical dose of either agent alone or a reduced dose of the FXR receptor agonist and/or the CCR5/CCR2 antagonist. The combination is effective to treat NASH with (1) enhanced efficacy and (2) substantial reduction of side effects, particularly those associated with administration of OCA or its analogues, namely less effect on liver enzyme elevation, and less severity and frequency of pruritus (3). The fixed dose combination provides for better efficacy and safety profile.
Inventors:
LAU WALTER (US)
WANG CHRISTOPHER (US)
SHO SHONAN (US)
WANG CHRISTOPHER (US)
SHO SHONAN (US)
Application Number:
PCT/US2017/068728
Publication Date:
August 09, 2018
Filing Date:
December 28, 2017
Export Citation:
Assignee:
MODUNEX BIO CORP (VG)
International Classes:
A61K31/575; A61K31/4178; A61K31/4375; A61K31/46; A61K31/506; A61P1/16; A61P11/00; A61P13/12
Attorney, Agent or Firm:
DAVIS, Steven G. et al. (US)
Download PDF:
Previous Patent: ABRASIVE PARTICLES WITH VITRIFIED BOND AND FILLER
Next Patent: DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME
Next Patent: DRIFT REDUCTION ADJUVANT COMPOSITIONS AND METHODS OF USING SAME